Neurolief develops wearable neuromodulation devices designed to treat neurological and psychiatric conditions through non-invasive stimulation. The company’s flagship system, Relivion, is intended for at-home use and targets multiple cranial nerve branches associated with pain and mood regulation. Its approach focuses on providing drug-free therapy through a wearable form factor. Neurolief positions its technology within regulated clinical treatment pathways rather than consumer wellness.

The technology delivers electrical stimulation to branches of the trigeminal and occipital nerves using a head-worn device. By stimulating multiple nerve pathways simultaneously, the system aims to modulate central neural circuits involved in migraine and depressive symptoms. Stimulation parameters are configurable and designed for repeated use under prescribed protocols. The platform emphasizes ease of use while maintaining alignment with clinical neuromodulation principles.

Neurolief targets patients with migraine and depression seeking non-pharmacological, home-based treatment options. The Relivion system is intended to be used within established medical frameworks, either as an alternative or complement to medication. Its positioning reflects broader efforts to expand access to neuromodulation therapies through wearable, patient-administered devices.